Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Target Price
The average target price of MDXH is 1.84 and suggests 184% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre